Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071937 · ClinicalTrials.gov registry record · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Alexander B Olawaiye, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05071937 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by Alexander B Olawaiye, MD. The registered enrollment target is 33 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05071937, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by Alexander B Olawaiye, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG ZEN003694
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2033-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05071937
The ClinicalTrials.gov registry entry for NCT05071937 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Alexander B Olawaiye, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.
NCT05071937 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05071937 about?
NCT05071937 is a clinical study titled "ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer". This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
What is the current status of trial NCT05071937?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-04-21. Estimated completion is 2033-03-01.
What conditions does trial NCT05071937 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT05071937?
The interventions under investigation include: Talazoparib (DRUG), ZEN003694 (DRUG).
Who is sponsoring clinical trial NCT05071937?
This trial is sponsored by Alexander B Olawaiye, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05071937 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
-
A Study of Isoquercetin in People With Ovarian Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.